Virtune launches Virtune Stablecoin Index ETP on Nasdaq Stockholm, Nasdaq Helsinki and Deutsche Börse Xetra Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology…
Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing…
Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results
AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…
VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update
PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults…
SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with…
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update
WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or…
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused…
OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update
Total Revenue for Q2 2021 was approximately $0.8 million Cash as of June 30, 2021…
Seer Reports Second Quarter 2021 Financial Results
Expanded installed base and booked initial revenue for Proteograph Product Suite REDWOOD CITY, Calif., Aug….
CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
Secured up to $100 million of additional development funding through a non-dilutive financing transaction with…
ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq:…
ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2021
Bottom Line: Q2 2021 Net Income of $141,000 versus Q2 2020 Net Loss of ($766,000) PORTLAND,…
Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights
Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trials Cash, cash…
Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results
Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of…
Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive…
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
— Topline data in ANG-3777 Phase 3 study now expected to be announced in early…
Motus GI Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Reported a 95% revenue increase versus Q1 2021; the fourth consecutive quarter of revenue growth…
89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
– Initiated Phase 2b ENLIVEN trial in NASH patients –– Completed enrollment in NASH histology…
Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights
– On Track to Report Initial Results from Phase 2 pheNIX Gene Therapy Trial for…
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results
New Data in Healthy Volunteers Confirmed that AT-527’s Active Metabolite Achieved Target Antiviral Levels in…